231 related articles for article (PubMed ID: 20975615)
41. Live attenuated varicella vaccine in healthy 12- to 24-month-old children.
Johnson CE; Shurin PA; Fattlar D; Rome LP; Kumar ML
Pediatrics; 1988 Apr; 81(4):512-8. PubMed ID: 2832819
[TBL] [Abstract][Full Text] [Related]
42. Advantage of a two-dose versus one-dose varicella vaccine in healthy non-immune teenagers and young adults.
Kosuwon P; Sutra S; Kosalaraksa P
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):697-701. PubMed ID: 15689090
[TBL] [Abstract][Full Text] [Related]
43. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989.
White CJ; Kuter BJ; Hildebrand CS; Isganitis KL; Matthews H; Miller WJ; Provost PJ; Ellis RW; Gerety RJ; Calandra GB
Pediatrics; 1991 May; 87(5):604-10. PubMed ID: 1850506
[TBL] [Abstract][Full Text] [Related]
44. The risk of zoster after varicella vaccination in children with leukemia.
Lawrence R; Gershon AA; Holzman R; Steinberg SP
N Engl J Med; 1988 Mar; 318(9):543-8. PubMed ID: 2828948
[TBL] [Abstract][Full Text] [Related]
45. Live attenuated varicella vaccine.
Gershon AA
Annu Rev Med; 1987; 38():41-50. PubMed ID: 3034136
[TBL] [Abstract][Full Text] [Related]
46. Varicella zoster vaccines.
Creed R; Satyaprakash A; Ravanfar P
Dermatol Ther; 2009; 22(2):143-9. PubMed ID: 19335725
[TBL] [Abstract][Full Text] [Related]
47. Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine.
Terada K; Niizuma T; Ogita S; Kataoka N
Vaccine; 2002 Nov; 20(31-32):3638-43. PubMed ID: 12399190
[TBL] [Abstract][Full Text] [Related]
48. Immunoglobulin subclass antibodies to varicella-zoster virus.
Asano Y; Hiroishi Y; Itakura N; Hirose S; Kajita Y; Nagai T; Yazaki T; Takahashi M
Pediatrics; 1987 Dec; 80(6):933-6. PubMed ID: 2825110
[TBL] [Abstract][Full Text] [Related]
49. Perspective on live varicella vaccine.
Gershon AA; Katz SL
J Infect Dis; 2008 Mar; 197 Suppl 2():S242-5. PubMed ID: 18419404
[TBL] [Abstract][Full Text] [Related]
50. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.
Pileggi GS; de Souza CB; Ferriani VP
Arthritis Care Res (Hoboken); 2010 Jul; 62(7):1034-9. PubMed ID: 20235203
[TBL] [Abstract][Full Text] [Related]
51. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
[TBL] [Abstract][Full Text] [Related]
52. Varicella zoster virus: vaccination and implications in children with renal failure.
Fadrowski JJ; Furth SL
Expert Rev Vaccines; 2004 Jun; 3(3):291-8. PubMed ID: 15176945
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity and safety of live attenuated and recombinant/inactivated varicella zoster vaccines in people living with HIV: A systematic review.
Carta V; Mangeri L; Tiecco G; Focà E; Quiros-Roldan E; De Francesco MA
Hum Vaccin Immunother; 2024 Dec; 20(1):2341456. PubMed ID: 38650460
[TBL] [Abstract][Full Text] [Related]
54. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).
Chou JF; Kernan NA; Prockop S; Heller G; Scaradavou A; Kobos R; Knowles MA; Papadopoulos EB; Casson A; Copeland C; Torok-Castanza J; Zakak N; Ruggiero J; Small TN
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1708-13. PubMed ID: 21664979
[TBL] [Abstract][Full Text] [Related]
55. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child.
Kramer JM; LaRussa P; Tsai WC; Carney P; Leber SM; Gahagan S; Steinberg S; Blackwood RA
Pediatrics; 2001 Aug; 108(2):E39. PubMed ID: 11483849
[TBL] [Abstract][Full Text] [Related]
56. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults.
Weinberg A; Levin MJ; Macgregor RR
Hum Vaccin; 2010 Apr; 6(4):318-21. PubMed ID: 20372089
[TBL] [Abstract][Full Text] [Related]
57. Postexposure varicella vaccination in nine-month-old children.
Kanra G; Ceyhan M; Ozmert E
Pediatr Infect Dis J; 2000 Oct; 19(10):1029-30. PubMed ID: 11055616
[No Abstract] [Full Text] [Related]
58. Evaluation of varicella vaccine in childhood leukemia. Observation over 6 years.
Oka T; Iseki K; Oka R; Sakuma S; Yoshioka H; Takahashi M
Biken J; 1984 Sep; 27(2-3):103-9. PubMed ID: 6100045
[TBL] [Abstract][Full Text] [Related]
59. Safety of a second dose of varicella vaccine administered at 4 to 6 years of age in healthy children in Argentina.
Fridman D; Monti A; Bonnet MC; Armoni J; Stamboulian D
Hum Vaccin; 2011 Oct; 7(10):1066-71. PubMed ID: 21989288
[TBL] [Abstract][Full Text] [Related]
60. Live varicella vaccine in severely immunodepressed children.
Ninane J; Latinne D; Heremans-Bracke MT; De Bruyere M; Cornu G
Postgrad Med J; 1985; 61 Suppl 4():97-102. PubMed ID: 3014486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
